Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics is a biopharmaceutical company leveraging AI-augmented literature intelligence for precision oncology research and cancer treatment.
Classification
Profile
Funding
Funding details not yet available.
Signals
AI-augmented literature intelligence to accelerate precision oncology research and cancer treatment discovery.
Biopharmaceutical companies and precision oncology research institutions.
Milestone payments & royalties from licensing OT-101, CA4P, Oxi4503 to larger pharma · Government contract funding (e.g., BARDA) for antiviral programs · Equity financing & public-market proceeds via OTCQB stock sales
Direct B2B outreach - scientific conferences, oncology symposia, and targeted webinars (e.g., TGF-β Summit) · Digital presence - corporate website, investor portal, and social media (Twitter, LinkedIn, YouTube) for stakeholder updates · Regulatory & grant portals - BARDA, FDA Fast Track submissions, and clinical-trial registries to signal progress
Contract Research Organizations (CROs) - for trial execution and data analysis · Academic institutions - collaborations on pediatric oncology and TGF-β biology · Government agencies - BARDA (COVID-19 antiviral work) and NIH grant programs
R&D for AI technology and pharmaceutical development expertise.
AI literature intelligence platform and leadership expertise in pharmaceutical development.
Developing AI tools for cancer and viral infection treatment information.
Scientific collaboration - co-development agreements, joint-research programs, and data-sharing with academic centers · Investor communication - quarterly earnings calls, press releases, and transparent SEC filings to maintain trust · Clinical-trial patient engagement - patient advocacy groups for rare pediatric cancers to build community support
Competes in biopharmaceutical and AI technology sectors; differentiates through AI-augmented literature intelligence.
Complexity of cancer and viral infection treatment information and precision oncology research challenges.
- Map a partnership pipeline targeting pharma firms with complementary checkpoint inhibitors; propose combination trials that leverage OT-1 · What are the latest developments in Oncotelic’s pipeline? · How does OT-101 work to treat cancer?
The website lists RPD designations for OT-101 in pediatric DIPG and a BARDA contract for COVID-19, both of which are strong external validat · The leadership team includes seasoned drug-development executives (CEO Vuong Trieu, PhD) with prior experience at FDA-regulated biotech firm · Publicly traded on OTCQB (OTLC), the company files regular SEC r
No investors recorded yet.